Clinical Study

A Prospective Randomized Controlled Trial of AJG522 versus Standard PEG + E as Bowel Preparation for Colonoscopy

Table 1

Patient demographics, reasons for colonoscopy, and comorbidities.

ParameterAJG522*PEG + ETotal

Number (%) of cases3233
Age (yr) 0.369
 Median6067
 Range26–8225–84
Gender, (%)0.622
 Male 16 (50.0%)16 (48.5%)
Reason for colonoscopy, (%)0.055
 Abdominal pain2 (6.3%)4 (12.1%)
 Bloody stool5 (15.6%)6 (18.2%)
 Follow-up after polypectomy5 (15.6%)8 (24.2%)
 Diarrhea0 (0%)3 (9.1%)
 Constipation1 (3.1%)2 (6.1%)
 Tumor screening3 (9.4%)4 (12.1%)
 Anemia2 (6.3%)0 (0%)
 Inflammatory bowel disease12 (37.5%)4 (12.1%)
 Other2 (6.3%)2 (6.1%)
Comorbidities, (%)0.518
 Diabetes mellitus5 (15.6%)2 (6.1%)
 Hypertension12 (37.5%)5 (15.2%)
 Rheumatoid arthritis2 (6.3%)0 (0%)
 Chronic kidney disease1 (3.1%)0 (0%)

AJG522: the solution contained 100.0 g macrogol 4000, 7.5 g sodium sulfate, 2.7 g sodium chloride, 1.0 g potassium chloride, 4.7 g ascorbic acid, 5.9 g sodium ascorbate, and green apple flavoring per liter; total dose = 2 L. PEG + E (Niflec): the solution contained 59.0 g macrogol 4000, 5.7 g sodium sulfate, 1.5 g sodium chloride, 0.7 g potassium chloride, 1.7 g sodium bicarbonate, and lemon flavoring per liter; total dose = 2 L.